The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing
antibodies and one of the most rapidly evolving domains, which can result in the emergence
of immune escape mutations, limiting the effectiveness of vaccines and antibody
therapeutics. To facilitate surveillance, we developed a rapid, high-throughput, multiplex
assay able to assess the inhibitory response of antibodies to 24 RBD natural variants
simultaneously. We demonstrate how this assay can be implemented as a rapid surrogate …